Exenatide (twice daily), liraglutide, lixisenatide (both once daily), oral semaglutide (once daily), and the once-weekly agents exenatide (Bydureon), albiglutide, semaglutide, and dulaglutide are among the GLP-1 RAs currently approved in the United States.[78–85] These drugs were initially only used to treat T2D because they effectively reduced A1C and weight. Here, GLP1R is linked to type 2 diabetes mellitus.